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Abstract
Cerebrotendinous xanthomatosis (CTX) is among the few inherited neurometabolic disorders amenable to specific
treatment. It is easily diagnosed using plasma cholestanol. We wished to delineate the natural history of the most
common neurological and non-neurological symptoms in thirteen patients with CTX. Diarrhea almost always
developed within the first year of life. Cataract and school difficulties usually occurred between 5 and 15 years of
age preceding by years the onset of motor or psychiatric symptoms. The median age at diagnosis was 24.5 years
old. It appears critical to raise awareness about CTX among paediatricians in order to initiate treatment before
irreversible damage occurs.
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Introduction
Cerebrotendinous xanthomatosis (CTX) is a rare auto-
somal recessive sterols storage disorder caused by 27-
sterol-hydroxylase deficiency due to CYP27A1 mutations
resulting in an accumulation of cholestanol in blood and
organs, mainly the central nervous system, eyes, tendons
and vessels [1, 2]. With an estimated prevalence of 1/
50,000 [3] but only about 300 patients reported, CTX re-
mains too often under- or misdiagnosed while treatment
is available. Patients typically manifest both systemic and
neuropsychiatric symptoms of the disease. Systemic
manifestations may include infantile cholestasis or liver
dysfunction, juvenile cataract, Achilles tendon xanthomas,
osteoporosis, premature arteriosclerosis and cardiovascu-
lar disease [1, 2, 4]. Neurological symptoms encompass
cognitive delay, spastic paraplegia, cerebellar ataxia,
peripheral neuropathy, bulbar palsy, epilepsy, movement
disorders, dementia and psychiatric disturbances [1, 2, 4].
While these symptoms are well described, their natural
history is not. More importantly, CTX is almost always di-
agnosed in adults whereas most of the initial symptoms
occur in childhood and adolescence. We therefore describe
the natural history of the most common neurological and
non-neurological symptoms in thirteen patients with CTX
in order to alert on the early symptoms of the disease.
Patients and methods
We collected retrospectively clinical, biochemical, imaging
and electrophysiological data from thirteen genetically con-
firmed CTX patients followed at La Pitié-Salpêtrière Uni-
versity Hospital. In order to delineate the natural history of
the disease, we selected only patients whose diagnosis was
made in adolescence or adulthood. Values are expressed in
mean ± SD and/or median. For the Kaplan-Meier analyses,
we assumed that patients are determined to have CTX at
birth. Therefore all time to event data (e.g. time to diarrhea,
time to cataract) assumed that the initial time was the date
of birth. The censoring time was the age at latest neuro-
logical exam. The symptoms were communicated via the
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caregiver or the patient directly. Each patient gave a written
informed consent to participate in the study. The study was
approved by the local ethics committee (CPPIdF6, La Pitié-
Salpêtrière University Hospital).
Results
We describe four males and nine females with CTX be-
longing to ten families. Four patients were born from a
consanguineous union (Additional file 1). All patients
Table 1 Clinical characteristics in a cohort of thirteen patients with CTX
Demographic
- Gender Female: 9 Male: 4
- Familial genetics Consanguinity: 4 Affected sibs: 6
Age of onset [median; mean ± SD; range] (years)
- Diarrhea 10/13, neonatal
- School difficulties 11/13 [10; 9.9 ± 3.2; 5–15]
- Cataract (age of surgery) 11/13 [13; 15.4 ± 13.8; 5–54]
- Psychiatric symptoms 6/13 [15.5; 21.2 ± 11.7; 10–40]
- Walking difficulties 11/13 [20; 21.4 ± 10.3; 12–50]
Neurological examination
Age at examination [median; mean ± SD; range] (years) 30; 33 ± 13.8 (18–60)
- Dysmetria Yes: 7/13
- Tandem Unable: 5/13 Abnormal: 7/13 Normal: 1/13
- LL spasticity Yes: 6/13
- UL spasticity Yes: 0/13
- LL reflexes (knee) Increased: 6/13 Absent: 3/13 Normal: 4/13
- LL reflexes (ankle) Increased: 5/13 Absent: 3/13 Normal: 5/13
- UL reflexes Increased: 9/13 Normal: 4/13
- Plantar reflexes Upgoing: 7/13 Flexor/Indifferent: 6/13
- Romberg Positive: 3/12 Negative: 9/12
- LL proprioception Decreased: 10/11 Normal: 1/11
- UL proprioception Normal: 11/11
Eye movements
- Pursuit Saccadic: 8/13 Normal: 5/13
- Saccades Dysmetric: 7/13 Normal: 6/13
Cognitive dysfunction 13/13
- Delayed cognition 10/13
- Dysexecutive/Decline 12/13
Paroxysmal manifestations




Peripheral neuropathy 10/13 - Axonal (4/10), Demyelinating (5/10), Mixed (1/10)
Brain MRI/MRS
- Global atrophy 3/13
- Periventricular T2 hyperintensities 10/13
- Increased choline peak (MRS) 13/13
- Dentate nuclei T2 hyperintensities 12/13
- Cerebellar atrophy 7/13
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were Caucasian except two patients of Turkish origin.
Six patients were compound heterozygous and five pa-
tients homozygous for CYP27A1 mutations. In two sib-
lings, the second mutation was not identified despite
very high levels of plasma cholestanol (Additional file 1).
In three families, the diagnosis of the index case led to
the diagnosis of a sibling. The mean and median age at
diagnosis were 30.4 ± 14.9 years and 24.5 years (range:
14-55) respectively. The mean and median disease dur-
ation at the time of diagnosis were 26.2 ± 11.6 years and
21.5 years (range: 13.5–54.5) respectively.
The natural history of our CTX cohort revealed that
chronic diarrhea was very common, starting within the
first year of life (Table 1, Fig. 1). None of our patients
had a known history of infantile hepatic dysfunction.
Cataract and school difficulties usually followed be-
tween 5 and 15 years of age (Additional file 1). Another
5–15 years later, most patients developed motor
dysfunction leading to walking difficulties and/or psy-
chiatric symptoms (Fig. 1, Additional file 1). Plasma
cholestanol was markedly elevated in all patients with a
mean of 64 ± 23 μmol/l (35–98 μmol/l, normal range:
2-10 μmol/l) (Additional file 1).
A detailed neurological evaluation was performed at a
median age of 30 years (18–60). Except for two patients
with no overt motor dysfunction, CTX patients presented
mainly with cerebello-pyramidal (6/13), neuropathic
(3/13), cerebellar (1/13) or pyramidal (1/13) dysfunc-
tion. Seven patients also displayed postural myoclonic
jerks associated with dystonia, including six that were
confirmed by electrophysiological recordings [5]. Cogni-
tive functions were altered in all patients and a neuropathy
was documented in ten patients (Table 1). On clinical
examination, only 3/13 patients had clinical tendon xan-
thomas (Table 1). Four patients developed osteopenia but
none experienced cardiac or pulmonary manifestations
(Table 1). Typically, brain MRI showed T2-weighted
hyperintensities of the dentate nuclei and brain MR spec-
troscopy identified an increased peak of choline in all
patients (Table 1).
Discussion
We describe the natural history of 13 patients with CTX.
Chronic diarrhea was the earliest symptom commonly ob-
served in CTX but did not seem to be a main cause for
consultation, possibly due to the absence of associated
growth retardation [6, 7]. Nonetheless, paediatric gastro-
enterologists should search for CTX in the context of an
early onset diarrhea, especially with a history of infantile
hepatic dysfunction. Similarly, the diagnosis of a cataract
in a child or an adolescent must lead to measure plasma
cholestanol. In our cohort, cataract and school difficulties
tended to occur at a similar age suggesting that visual dif-
ficulties may contribute to the early cognitive difficulties
of some CTX patients. Years after the onset of diarrhea,
cataract and/or school difficulties, many patients devel-
oped gait abnormalities primarily related to cerebellar
and/or pyramidal dysfunction and combined with cogni-
tive dysfunction. About half of our cohort also developed
psychiatric symptoms. Tendon xanthomas were rarely
found on clinical examination, which emphasizes that
their absence should not delay the diagnosis of CTX [6].
Electromyography often revealed a peripheral neuropathy
with either an axonal or a demyelinating pattern. Brain
MRI also showed T2-weighted hyperintensities of the den-
tate nuclei and are suggestive of the diagnosis [8]. The in-
creased peak of choline on MR spectroscopy might be
useful to monitor response to therapy.
It has been shown that non-neurological and neuro-
logical manifestations can respond to chenodeoxycholic
acid (CDCA) through decreased plasma cholestanol
levels [1, 4, 9]. When initiated early, the therapeutic re-
sponse to CDCA can be dramatic [10, 11]. Therefore,
paediatricians must be at the forefront of diagnosing
CTX in children with chronic diarrhea and/or cataract
and/or learning difficulties. Indeed, such symptoms con-
stitute an important therapeutic window to initiate treat-
ment in patients with CTX before the onset of disabling
motor and psychiatric symptoms.
Fig. 1 Kaplan–Meier analyses indicate the natural history of thirteen
patients with CTX for time to diarrhea, cataract, school difficulties,
walking difficulty and psychiatric symptoms
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Conclusion
Our work shows that CTX is almost always diagnosed in
adults whereas key symptoms occur in childhood and
adolescence. Treatment shall be initiated before the on-
set of disabling motor and psychiatric symptoms.
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